TGFB2 and non-small cell lung carcinoma: Moreover, our omics profiling study revealed profound genome- and metabolome-wide cellular reprogramming within EGFR-mutant NSCLC cells undergoing early drug-escape, mediated by TGFβ2 autocrine signaling.